ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics


ClearPoint Neuro, Inc. (CLPT): $18.88

-0.43 (-2.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CLPT POWR Grades


  • CLPT scores best on the Sentiment dimension, with a Sentiment rank ahead of 84.35% of US stocks.
  • CLPT's strongest trending metric is Stability; it's been moving down over the last 31 weeks.
  • CLPT's current lowest rank is in the Stability metric (where it is better than 13.08% of US stocks).

CLPT Stock Summary

  • CLPT's price/sales ratio is 29.19; that's higher than the P/S ratio of 92.13% of US stocks.
  • With a year-over-year growth in debt of 59.06%, ClearPoint Neuro Inc's debt growth rate surpasses 87.24% of about US stocks.
  • The volatility of ClearPoint Neuro Inc's share price is greater than that of 92.47% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CLPT, based on their financial statements, market capitalization, and price volatility, are INVE, REKR, ALLT, SILK, and AWH.
  • CLPT's SEC filings can be seen here. And to visit ClearPoint Neuro Inc's official web site, go to www.clearpointneuro.com.

CLPT Price Target

For more insight on analysts targets of CLPT, see our CLPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.5 (Moderate Buy)

CLPT Stock Price Chart Interactive Chart >

Price chart for CLPT

CLPT Price/Volume Stats

Current price $18.88 52-week high $31.29
Prev. close $19.31 52-week low $3.15
Day low $18.66 Volume 237,400
Day high $19.37 Avg. volume 407,794
50-day MA $19.04 Dividend yield N/A
200-day MA $15.23 Market Cap 391.97M

ClearPoint Neuro, Inc. (CLPT) Company Bio


ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.


CLPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CLPT Latest Social Stream


Loading social stream, please wait...

View Full CLPT Social Stream

Latest CLPT News From Around the Web

Below are the latest news stories about ClearPoint Neuro Inc that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

ClearPoint Neuro, Inc. Announces Installation of ClearPoint® 2.0 Software at Mazowiecki Szpital Bródnowski in Poland

SOLANA BEACH, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the installation of its version 2.0 software at Mazowiecki Szpital Bródnowski in Warsaw, Poland. “We appreciated the patience and commitment of the on-site ClearPoint team throughout the installation process,” stated Professor Mirosław Ząbek, Head of the Neurosurgery Clinic at Mazowiecki Szpital B

Yahoo | June 16, 2021

ClearPoint Neuro Set to Join Russell 3000® Index

SOLANA BEACH, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4. The annual Russell indexes reconstitution captures the 4,000 largest U

Yahoo | June 14, 2021

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease

First Ever Stem Cell Clinical Trial Patient Treated Using Entire ClearPoint Platform ClearPoint Neuro ClearPoint Neuro Navigation Platform for Drug Delivery SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, on the dose ad

Yahoo | June 8, 2021

US$35.00 - That's What Analysts Think ClearPoint Neuro, Inc. (NASDAQ:CLPT) Is Worth After These Results

ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its quarterly report and things are looking bullish. Revenues of...

Yahoo | May 13, 2021

Earnings Preview: ClearPoint Neuro, Inc. (CLPT) Q1 Earnings Expected to Decline

ClearPoint Neuro, Inc. (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 4, 2021

Read More 'CLPT' Stories Here

CLPT Price Returns

1-mo 2.05%
3-mo -16.42%
6-mo 32.03%
1-year 402.13%
3-year 703.40%
5-year 140.82%
YTD 18.82%
2020 231.04%
2019 205.73%
2018 -42.91%
2017 -19.12%
2016 -77.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7745 seconds.